su11274

SU11274 is a **small molecule**, ATP-competitive, and selective inhibitor of the **MET receptor tyrosine kinase** (also known as c-Met), with an IC50 in the range of 10–20 nM[3][5][8]. It inhibits MET activation and autophosphorylation, modulates MET-driven cell proliferation, survival, motility, and anchorage-independent growth[3][4][5][7][8]. Preclinical studies show activity in models of human cancers with aberrant MET activation, including melanoma, pancreatic cancer, colorectal cancer, and non-small-cell lung cancer[2][4][6][8]. SU11274 has been shown to suppress cell proliferation and motility, induce G1-phase arrest, modulate stem/pluripotency marker expression, and alter cell bioenergetics[2][4][8]. As a research compound, it has been studied for understanding MET signaling, cancer biology, and targeted therapy.

Other names

su11274su-11274su 11274